A clinical-stage biotechnology company focused on precision medicine to develop next-generation neuroscience therapies announced its upcoming activities at the 2024 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP)…
Nutcracker Therapeutics, a biotechnology company focused on developing transformative RNA therapies through its proprietary technology platform, announced the presentation of key prostate cancer antigen research by its partners at the…
VBI Vaccines Inc. (Nasdaq: VBIV) Announces Q1 2024 Business Update and Financial Results VBI Vaccines Inc. (Nasdaq: VBIV), a biopharmaceutical company focused on immunology to develop potent disease prevention and…
Legend Biotech Corporation (NASDAQ: LEGN), a global pioneer in cell therapy, unveiled its unaudited financial performance for the first quarter of 2024 alongside notable corporate achievements. Dr. Ying Huang, CEO…
Incyte Corporation (Nasdaq:INCY) announced today that its Board of Directors has greenlit a $2.0 billion share repurchase program. As part of this initiative, the company has initiated a modified “Dutch…
Eisai announced today that it has received approval in China for an additional indication of its antiepileptic drug (AED) Fycompa® (generic name: perampanel hydrate) for adjunctive treatment of primary generalized…
UCB, a global biopharmaceutical company, announced that the Journal of Neurology has published data from the Phase 3 RAISE study and the ongoing RAISE-XT open-label extension (OLE) study on the…
Baxter, a global leader in nutrition therapy, announced the U.S. FDA’s approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) for use in pediatric patients, including preterm and term…
Astellas Pharma Inc. will present new research from its innovative cancer therapies portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4.…
In its quarterly qualitative update, Lonza reported a softer Q1, with performance across H1 expected to align with the full-year 2024 trajectory. Lonza confirms its 2024 outlook, projecting flat sales…
The Bayer Group’s performance in the first quarter of the year met expectations, according to CEO Bill Anderson. “First-quarter sales declined slightly versus the prior year. The Pharmaceuticals Division saw…
Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, global option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including…